Navigation Links
Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
Date:7/9/2009

SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R788 (fostamatinib disodium) produced significant clinical improvement in rheumatoid arthritis (RA) patients in the recently completed TASKi2 Phase 2b clinical trial of 457 patients treated for up to 6 months. The groups treated with 100 mg of R788 bid (twice a day) and 150 mg qd (once a day) reported higher ACR 20, ACR 50, ACR 70 and DAS28 response rates than the placebo group. The efficacy results for the two dosing groups were comparable, although the response rates for the 100 mg bid group was uniformly greater. Consistent with the previous Phase 2a clinical trial (TASKi1), the onset of effect of R788 occurred within one week after the initiation of therapy and was maintained. The most frequent adverse events were expected based on TASKi1 and appear to be manageable. The significant, early and sustained efficacy, combined with a good safety profile, supports Rigel's plans to conduct corporate partnership discussions with respect to R788 and initiate a Phase 3 clinical program with R788 in RA in the first half of 2010 with a corporate partner.

Rigel will host a conference call today at 8:00am EDT/5:00am PDT to discuss these results (see conference call details below).

"These are impressive results," said James M. Gower, chairman and chief executive officer of Rigel. "The data from this clinical trial and the soon to be completed TASKi3 clinical trial, a total of over 670 patients, will guide the design of the Phase 3 trials that we plan to launch with a corporate partner in the first half of next year, " he added.


    Efficacy Results

    Treatment    N of Pts   ACR 20     ACR 50    ACR 70    DAS28<2.6

    Placebo        153      53 (35%)   29 (19%)  16 (10%)  9 (
'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
7. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
8. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
9. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
10. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- CHINA AID, the 10 ... Medicine and Healthcare, second to none in ... at Shanghai New International Expo Center on 22-24 April. ... on Encouraging Private Capital to Participate in the Development ... by the Ministry of Civil Affairs of the ...
(Date:3/27/2015)... , March 27, 2015  Valeant Pharmaceuticals International, Inc. ... closing of its previously announced registered offering of common ... (the "Offering"). Pursuant to the Offering, the Company issued ... share, for aggregate gross proceeds of approximately $1.45 billion. ... U.S. Securities and Exchange Commission a final prospectus supplement ...
(Date:3/27/2015)... , March 27, 2015 As of ... of incontinence devices for women. "Shipping ... most gratifying part is the hundreds of letters, ... whose lives have been positively impacted by our ... InControl. InControl recently released Apex, an ...
Breaking Medicine Technology:CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
... 2011 The National Community Pharmacists Association ... Consumer Choice Act of 2011 , which would ... of their choice, eliminate needless pharmaceutical spending and ... audits. (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ...
... May 24, 2011 CVS Caremark today outlined ... program designed to encourage patients to take their ... program show increases in consumers signing up for ... medications for brand medicines to lower costs. ...
Cached Medicine Technology:Community Pharmacists Endorse Bipartisan Pharmacy Competition and Consumer Choice Act 2Community Pharmacists Endorse Bipartisan Pharmacy Competition and Consumer Choice Act 3CVS Caremark Research Tailors Consumer Communications to Encourage Better Medication Behavior 2CVS Caremark Research Tailors Consumer Communications to Encourage Better Medication Behavior 3
(Date:3/28/2015)... (PRWEB) March 28, 2015 How best ... a growing field in orthopaedic medicine. While diagnostic hip ... to confirm the pain etiology, research presented today at ... ) Specialty Day suggests that pain relief from this ... hip surgery. , “Our study looked to assess ...
(Date:3/28/2015)... Andrew Hawley of Vintage Rock Posters Inc., ... posters. The Who and the Doors played together at the ... According to Hawley, “The Who toured the United States heavily ... campuses. Perhaps the most famous Who poster was a poster ... Doors on August 2, 1968 at the Singer Bowl in ...
(Date:3/28/2015)... The "Petrick Sustainable Health System" ... After 18 years of research and experience with patients ... Dr. Jon Petrick is excited to be launching his ... the immediate benefits of this radical new system are ... strength of the immune system, faster healing of injuries, ...
(Date:3/28/2015)... Servpro of Paso Robles , ... report about the link between mold and asthma. Mold ... to recent medical research, may even cause asthma in ... Protection Agency, people with sensitivity to mold or mold ... trigger asthma attacks for asthma sufferers. The EPA recommends ...
(Date:3/27/2015)... In her mid-forties and with a lifelong ... Monica K. arrived at JET Uniform & Supply ... and scared. The owners and staff at JET, which had ... to offer jobs to challenged residents like Monica, were patient. ... to begin with the end in mind,” says Stephen Milaney, ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For&nbsp;Original 1960's Who Psychedelic Concert Posters. 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3
... Rock Enterprises President and Chief,Operating Officer Matthew P. ... Metropolitan Detroit. Cullen succeeds Bill Baer, president and,chief executive ... of the work the YMCA does throughout the Metro ... said. "The YMCA has been a vital part of ...
... ... Market, BEDFORD, Mass. and ... Mass., announced today that it,has signed a definitive agreement to acquire Third ... per share, or approximately,$580 million in value, representing an approximately 24% premium ...
... pressure monitoring and pedometer drivers allow consumers to ... health information via HealthVault, BANNOCKBURN, Ill., June ... relationship to support Microsoft HealthVault,Microsoft,s consumer health platform, ... and a pedometer (HJ-720ITC) to be,compatible and share ...
... will be presented on Monday at SLEEP 2008, the ... (APSS), finds that poor sleep is a problem in ... Julie L. Elam, of Indiana University, was based on ... 48 years. Seventy-six percent of the participants were ...
... negative effect on a student academically, the sleep variables ... to a research abstract that will be presented on ... the Associated Professional Sleep Societies (APSS). , The study, ... Colorado, focused on 98 junior high, 67 high school, ...
... be presented on Monday at SLEEP 2008, the 22nd Annual ... first description of nicotine use by narcolepsy patients. Because ... even while eating, walking or driving, those who smoke nicotine ... themselves or the objects around them, or starting a fire, ...
Cached Medicine News:Health News:Cullen Elected to Chairman of YMCA of Metro Detroit - the City's Oldest Not-for-Profit 2Health News:Hologic to Acquire Third Wave Technologies 2Health News:Hologic to Acquire Third Wave Technologies 3Health News:Hologic to Acquire Third Wave Technologies 4Health News:Hologic to Acquire Third Wave Technologies 5Health News:Hologic to Acquire Third Wave Technologies 6Health News:Hologic to Acquire Third Wave Technologies 7Health News:Hologic to Acquire Third Wave Technologies 8Health News:Hologic to Acquire Third Wave Technologies 9Health News:Hologic to Acquire Third Wave Technologies 10Health News:Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault 2Health News:Omron Healthcare Introduces New Device Drivers Built on Microsoft HealthVault 3Health News:Poor sleep a problem in long-term breast cancer survivors 2Health News:Sleep variables affecting school performance are different with each educational level 2Health News:Potential dangers faced by narcoleptics who use nicotine outlined in new abstract 2
... and Maximum ACT introducers represent the ... hemostasis introducers in the world. They ... introducers for use in interventional cardiology ... stenting, atherectomy, temporary pacing, endomyocardial biopsies, ...
The intended use of the percutaneous PREFACE Guiding Sheath is for the introduction of intravascular electrophysiology catheters into any cardiac chamber....
... Fast-Cath, Maximum, Maximum Xtra, and Maximum ... of standard and specialty hemostasis introducers ... as the premier hemostasis introducers for ... procedures including angiography, angioplasty, stenting, atherectomy, ...
Rapid Exchange Stent Delivery System with Hepacoat...
Medicine Products: